Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare

Hamostaseologie

Volumn 29, Issue 2, 2009, Pages 137-142

  Eberl, W ^a   Budde, U ^b   Bentele, K ^c   Christen, H J ^d   Knapp, R ^a   Mey, A ^c   Schneppenheim, R ^d  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

^b Coagulation Laboratory   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Children's Hospital Auf der Bult   (Germany)

Author keywords

Acquired von Willebrand syndrome; Valproic acid

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRINOGEN; VALPROIC ACID; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TIME; CHILD; CLINICAL ARTICLE; EPILEPSY; FEMALE; HUMAN; LABORATORY TEST; MALE; PROTEIN DETERMINATION; RANK SUM TEST; SIDE EFFECT; THROMBOCYTE COUNT; VON WILLEBRAND DISEASE;

EID: 66749101732     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617026     Document Type: Article

References (28)

1. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate J Pediatr Hematol Oncol 2000; 22: 62-65.
2. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 (Suppl 3): 53-59.
3. Banerjea M, Diener W, Kutschke G et al. Valproat und Hamostase. In: Gross-Selbeck G (Hrsg). Aktuelle Neuropadiatrie 1995. Ciba-Geigy 1996.
4. Banerjea MC, Diener W, Kutschke G et al. Pro- and anticoagulatory factors under sodium valproate-therapy in children Neuropediatrics 2002; 33: 215-220.
5. Barr RD, Copeland SA, Stockwell ML et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57: 681-684.
6. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-466.
7. Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978; 1: 1316-1317.
8. Delgano MR, Riela AR, Mills J. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994; 9: 311-314.
9. Gidal B, Spencer N, Maly M et al. Valproate-me- diated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994; 44:1418-1422.
10. Gill JC, Endres-Brooks J, Bauer PJ et al. The effect of ABO blood group on the diagnosis of von Wille-brand disease. Blood 1987; 69: 1691-1695.
11. auser E, Seidl R, Freilinger M et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996; 18: 105-109.
12. Jacobi G, Thorbeck R, Ritz A et al. Fatal hepatot- oxicity in child on phenobarbitone and sodium val-proate. Lancet 1980; 1(8170): 712-713.
13. Konig SA, Eiger CE, Vasella F. Empfehlungen zur Blutuntersuchung und der klinischen Uber-wachung zur Fruherkennung des Valproat-asso-ziierten Leberversagens. Mschr Kinderheilk 1999; 147: 718-723.
14. Kreuz W, Linde R, Funk M et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33: 178-184.
15. Kreuz W, Linde R, Funk M et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335: 1350-1351.
16. Kreuz W, Mentzer D, Becker S et al. Haemate P in children with von Willebrand's disease. Haemostasis 1994; 24: 304-310.
17. Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia 1981; 22: 141-146.
18. Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979; 5: 389-390.
19. Nitu-Whalley IC, Lee CA, Griffioen A et al. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-264.
20. Ojemann LM, Wilensky AJ. Fibrinogen and val- proic acid. Epilepsia 1981; 22: 242-243.
21. Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003; 108: 142-145.
22. Sadler JE. A revised classification of von Willebrand disease. For the subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-525.
23. Sandler RM, Bevan PC, Roberts GE et al. Interaction between sodium valproate and platelets: a further study. Br Med J 1979; 2: 1476.
24. Voss H, Petrich C, Schulz HU. Hemorrhagic diathesis and platelet dysfunction in children under treatment with sodium valproate. Epilepsia 1978; 19: 113-114.
25. Serdaroglu G, Tutuncuoglu S, Kavakli K, Tekgul H. Coagulation abnormalities and acquired von Wille- brand's disease type 1 in children receiving valproic acid. J Child Neurol. 2002; 17: 41-43.
26. Sussman NM, McLain LW Jr. A direct hepatotoxic effect of valproic acid. JAMA 1979; 242: 1173-1174.
27. Sutor AH, Jesdinsky-Buscher. Gerinnungsverande- rungen durch Dipropylessigsaure. Med Welt 1974; 25: 447-449.
28. Zeitler P, Mingers AM. Gerinnungsveranderungen unter Valproattherapie. Mschr Kinderheilk 1995; 143: 949.